Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer

PURPOSE: Trilaciclib is a first-in-class CDK4/6 inhibitor that transiently arrests hematopoietic stem and progenitor cells (HSPCs) in the G1 phase of the cell cycle to preserve them from chemotherapy-induced damage (myelopreservation). We report integrated analyses of preclinical and clinical data t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Li, Chao, Hart, Lowell, Owonikoko, Taofeek K., Aljumaily, Raid, Rocha Lima, Caio Max, Conkling, Paul R., Webb, Roy Timothy, Jotte, Robert M., Schuster, Steven, Edenfield, William J., Smith, Deborah A., Sale, Mark, Roberts, Patrick J., Malik, Rajesh K., Sorrentino, Jessica A.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8026479/
https://ncbi.nlm.nih.gov/pubmed/33595690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-021-04239-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados